

A Molecular View on the *i*RGD Peptide Binding Mechanism: Implications for Integrin Activity and Selectivity Profile

Vincenzo Maria D'Amore,^{1,‡} Greta Donati,^{1,‡} Elena Lenzi,² Beatrice Stefanie Ludwig,³ Susanne Kossatz,^{3,4} Monica Baiula,⁵ Andrea Trabocchi,² Horst Kessler,⁴ Francesco Saverio Di Leva,^{1,*} Luciana Marinelli^{1,*}

¹ Department of Pharmacy, Università degli Studi di Napoli "Federico II", Via D. Montesano 49, 80131 Naples, Italy.

² Department of Chemistry "Ugo Schiff", University of Florence, via della Lastruccia 13, I-50019 Sesto Fiorentino, Florence, Italy.

³ Department of Nuclear Medicine, University Hospital Klinikum Rechts der Isar and Central Institute for Translational Cancer Research (TranslaTUM), Technical University Munich, Munich, 81675, Germany

⁴ Department of Chemistry, Institute for Advanced Study, Technical University Munich, Garching, 85748, Germany

⁵ Department of Pharmacy and Biotechnology, University of Bologna, Via Imerio 48, 40126 Bologna, Italy

KEYWORDS: RGD Integrins, Tumor-homing peptides, Computational Chemistry, Drug Design, Metadynamics


Supporting Information

TABLE OF CONTENTS

Table S1: Primary sequence of peptides 1-11.	p. S2
Figure S1: Convergence of the PT-WTE simulation.	p. S3
Figure S2: Replica exchange plots of the PT-WTE simulation.	p. S4
Figure S3: Multiple sequence alignment of selected RGD integrins heads.	p. S5
Figure S4: Local multiple sequence alignment of integrins SDL region.	p. S5
Figure S5: Validation of the $\alpha\beta 5$ homology model.	p. S6
Figure S6: Docking predicted binding poses.	p. S7
Figure S7: Interatomic distances of <i>i</i> RGD with ($\beta 5$)-T315 and ($\beta 5$)-N317.	p. S8
Figure S8: Upward rotation of <i>i</i> RGD during the MD simulation in complex with $\alpha\beta 5$.	p. S8
Figure S9: Analysis of the <i>i</i> RGD- $\alpha\beta 3$ interactions.	p. S9
Figure S10: Analysis of the <i>i</i> RGD- $\alpha\beta 5$ interactions.	p. S10
Figure S11: Stability of the peptide conformation during the <i>i</i> RGD- $\alpha\beta 3$ MD run.	p. S11
Figure S12: Stability of the peptide conformation during the <i>i</i> RGD- $\alpha\beta 5$ MD run.	p. S12
Figure S13: Analysis of the <i>i</i> RGD- $\alpha\beta 6$ interactions.	p. S13
Figure S14: RGD binding pattern assumed by <i>i</i> RGD in $\alpha\beta 6$.	p. S14
Figure S15: Analysis of the <i>i</i> RGD's ϕ -Gly3 and ψ -Asp ⁴ torsion values during MD runs.	p. S14
Figure S16: Stability of the peptide conformation during the <i>i</i> RGD- $\alpha\beta 6$ MD run.	p. S15
Figure S17: Cartoon representation of the integrins' RGD binding site and SDL cavity.	p. S15
Figure S18: Punctiform mutations occurring at the SDL pocket of the $\beta 3$, $\beta 5$ and $\beta 6$ subunits.	p. S16
Figure S19: Superposition between the MD poses of <i>i</i> RGD at $\alpha\beta 3$ and $\alpha\beta 5$ and cilengetide.	p. S17
Figure S20: PT-WTE-predicted folding Free Energy Surfaces of compounds 3-7.	p. S18
Figure S21: PT-WTE-predicted folding Free Energy Surfaces of compounds 8-11.	p. S19

Table S1. Primary sequence of **1-11**. Compounds **3-11** are virtually designed peptides.

Compound	Sequence
1 (iRGD)	Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys
2	[Arg-Gly-Asp-Chg-Glu]-CONH ₂
3	Cys-Arg-Gly-Asp-Lys-Val-Pro-Asp-Cys
4	Cys-Arg-Gly-Asp-Lys-Leu-Pro-Asp-Cys
5	Cys-Arg-Gly-Asp-Lys-Ile-Pro-Asp-Cys
6	Cys-Arg-Gly-Asp-Lys-Phe-Pro-Asp-Cys
7	Cys-Arg-Gly-Asp-Lys-Trp-Pro-Asp-Cys
8	Cys-Arg-Gly-Asp-Lys-Chg-Pro-Asp-Cys
9	Cys-Arg-Gly-Asp-Lys-Cha-Pro-Asp-Cys
10	Cys-Arg-Gly-Asp-Lys-Alg-Pro-Asp-Cys
11	Cys-Arg-Gly-Asp-Lys-Cpa-Pro-Asp-Cys






Figure S2. Replica exchange plots of the PT-WTE simulation. A) Replica index found at each selected temperature as a function of time. B) Temperature at which each individual replica is simulated as function of time. The average round trip time with its standard error is 0.573 ± 0.015 ns.

CLUSTAL O(1.2.4) multiple sequence alignment

```

sp|P26012|ITB8_HUMAN      KKYPVDLYYLVDVSASMHNIIEKLSVGNLDSRKMAFFSRDFRLGFGSYVDKTVSPYISI
sp|P05556|ITB1_HUMAN      EDYPIDLYYLMDLSSMKDDLENVKSLGTDLMNEMRRITSDFRIGFGSFVEKTVMPYIST
sp|P18564|ITB6_HUMAN      EDYPVDLYYLMDLSSAMDDDLNTIKELGSRLSKEMSKLTSNFRLLGFGSFVEKPVSPFVK
sp|P05106|ITB3_HUMAN      EDYPVDIYYLMDLSYSMKDDLWSIQNLGTLATQMRKLTSNLRIIGFGAFVDPKPVSPYMI
sp|P18084|ITB5_HUMAN      EDYPVDLYYLMDLSSLKDDLDNIRSLGTLAEEMRKLTSNFRLLGFGSFVDKDISPFSYT
      :.*:.*:.*:.*:.* *.*:..: .*..:.*. * :.* :.: :.*:.*:.*:.*:.* :.*:

sp|P26012|ITB8_HUMAN      HPE-RIHNCSDY--NLDCMPPHGYIHVLSLTENITEFEKAVHRQKISGNIDTPEGGFDA
sp|P05556|ITB1_HUMAN      TPA-KLRNPCTS---EQNCTSPFSYKNVLSLTNKGEVFNELVGGKQRIISGNLDSPEGGFDA
sp|P18564|ITB6_HUMAN      TPE-EIANPCSS--IPYFCLPTFGFKHILPLTND AERFNEIVKNQKISANIDTPEGGFDA
sp|P05106|ITB3_HUMAN      SPPEALENPCY--DMKTTCLPMFGYKHLVLTLDQVTRFNEEVKQSVSRNRDAPEGGFDA
sp|P18084|ITB5_HUMAN      APR-YQTNPCIGYKLPNCVPSFGFRHLLPLTDRVDSFNEEVKQSVSRNRDAPEGGFDA
      *   * *           *   ..: :.* :.*:   *.: * . * : * * :.*:.*:.*:.*:

sp|P26012|ITB8_HUMAN      MLQAAVCESHIGWRKEAKRLLLVMTDQTSHLALDSKLAGIVVPNDGNCHLK-NINVVYKST
sp|P05556|ITB1_HUMAN      IMQVAVCGSLIGWRNV-TRLLVFDAGFHAGDGKLGIVLPNDGQCHLE-NINMYTMSH
sp|P18564|ITB6_HUMAN      IMQAAVCKEIKGWRNDSLHLLVFDADSHFGMDSKLAGIVIPNDGQCHLDSKNEYSMST
sp|P05106|ITB3_HUMAN      IMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPDGQCHVSGDNHYSAST
sp|P18084|ITB5_HUMAN      VLQAAVCKEIKGWRKDALHLLVFTTDDVPHIALDGKLGGLVQPHDGQCHLNEANEYTASN
      :.*:.*:.* . *.*:.*: :.*:..: . * :.*. *.:.*:.*:.*:.*: * * *

sp|P26012|ITB8_HUMAN      TMEHPSLGQLSEKLIENNINIVFAVQKQFHWYKDLPLLPGTIAGEIESKAANLNNLVV
sp|P05556|ITB1_HUMAN      YYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTLSANSSNVIQLII
sp|P18564|ITB6_HUMAN      VLEYPTIGQLIDKLVQNNVLLIFAVTQEQQVHLYENYAKLIPGATVGLLQKDSGNILQLII
sp|P05106|ITB3_HUMAN      TMDYPSLGLMTEKLSQKNINLIFAVTENVVNLQNYSELIPGTTVGLSMDSSNVLQLIIV
sp|P18084|ITB5_HUMAN      QMDYPSLALLGEKLAENNINLIFAVTKNHYMLYKNFTALIPGTTVEILDGDSKNIIQLII
      :.*:..: . :.*: :.*: *.*: * : *.: *.* : . .. . * : :.*:

sp|P26012|ITB8_HUMAN      EAYQKLIS
sp|P05556|ITB1_HUMAN      DAYNSLSS
sp|P18564|ITB6_HUMAN      SAYEELRS
sp|P05106|ITB3_HUMAN      DAYGKIR-
sp|P18084|ITB5_HUMAN      NAYNSIR-
      .** .:

```

Figure S3. Multiple sequence alignment between the “head” residues (corresponding to $\beta 3$ residues 107-352) of all the human RGD β -subunits ($\beta 1$, $\beta 3$, $\beta 5$, $\beta 6$, $\beta 8$) performed with the ClustalOmega software.

CLUSTAL O(1.2.4) SDL sequence alignment

```

sp|P05556|ITB1_HUMAN      VMPYISTT-PAKLRNPCTSEQ---NCTSPFSY
sp|P18084|ITB5_HUMAN      ISPFSYTA-PRYQTNPCIGYKLPNCVPSFGF
sp|P05106|ITB3_HUMAN      VSPYMYISPPEALENPCYDMKT--TCLPMFGY
sp|P26012|ITB8_HUMAN      VSPYISIH-PERIHNCSDYNL--DCMPPHGY
sp|P18564|ITB6_HUMAN      VSPFVKTT-PEEIANPCSSIPYF--CLPTFGF
      : * :      *   * * .      *   ..:

```

Figure S4. Multiple sequence alignment between the SDL residues (corresponding to $\beta 3$ residues 161-192) of all the human RGD β -subunits ($\beta 1$, $\beta 3$, $\beta 5$, $\beta 6$, $\beta 8$) performed with the ClustalOmega software.





Figure S5. A) Ramachandran plot of the $\alpha\beta 5$ homology model and B) RMSD plot of the secondary structure element ($C\alpha$ atoms) over the 2 μs long MD simulation of $\alpha\beta 5$ in complex with *i*RGD.




Figure S6. Docking-predicted binding mode of *i*RGD at the RGD binding site of $\alpha\text{V}\beta\text{3}$, $\alpha\text{V}\beta\text{5}$ and $\alpha\text{V}\beta\text{6}$ integrins. The different receptors subunits are depicted as colored surfaces (αV =grey, β3 =red, β5 =cyan and β6 =green). Amino acids important for peptide binding are highlighted as sticks, while the Mg^{2+} ion in the MIDAS is shown as a purple sphere. The ligand is represented as orange ribbon and sticks; nonpolar hydrogens are omitted for sake of clarity; and H-bonds are shown as black dashed lines.




Figure S7. Interatomic distances between the C-ter carboxylic carbon of *i*RGD's Cys⁹ with T315-Oγ¹ (A) and N317-Cγ (B). The bolded lines show values of the distance smoothed with a rolling window of 5 ns, while the actual fluctuations are shown with a slight transparency.




Figure S8. 3D representation of the upward rotation experienced by *i*RGD during the first stages of the MD simulation in complex with the $\alpha\beta 5$ receptor. The grey arrow represents the axis of the rotation. The receptor is depicted as light gray (αv subunit) and cyan ($\beta 5$ subunit) surfaces. The ligand backbone is shown in orange (initial MD frame) and red (final MD frame) cartoons, while the sidechain of Arg² and Asp⁴ are as shown as sticks to highlight the typical RGD binding pattern. The divalent Mg²⁺ cation at the MIDAS is depicted as a purple sphere.




Figure S9. Analysis of the *i*RGD- α v β 3 residues interactions along the MD simulation. A) Frequency of Occurrence (% of collected frames in which the contact is formed) of the interatomic interactions: (I) Arg² (C ζ atom) – (α v)-D218 (C γ atom); (II) Asp⁴ (C ζ atom) – (β 3)-Mg²⁺; (III) Asp⁴ (C ζ atom) – (β 3)-S121 (O γ atom); (IV) Asp⁴ (backbone-N atom) – (β 3)-R216 (backbone-O atom); (V) Lys⁵ (backbone-O atom) – (β 3)-R214 (N ζ atom); (VI) Pro⁷ (Center of Mass of the pyrrolidine ring) – (α v)-Y178 (Center of Mass of the phenol ring) B) Evolution of the interatomic distances of contacts (I) – (VI) over the MD timescale. In each plot, the adopted cutoff (5.5 Å) is shown as a dashed black line.




Figure S10. Analysis of the *i*RGD- α v β 5 residues interactions along the MD simulation. A) Frequency of Occurrence (% of collected frames in which the contact is formed) of the interatomic interactions: (I) Arg² (C ζ atom) – (α v)-D218 (C γ atom); (II) Asp⁴ (C ζ atom) – (β 5)-Mg²⁺; (III) Asp⁴ (C ζ atom) – (β 5)-S126 (backbone-N atom); (IV) Asp⁴ (backbone-N atom) – (β 5)-D221 (backbone-O atom); (V) Pro⁷ (Center of Mass of the pyrrolidine ring) – (α v)-Y178 (Center of Mass of the phenol ring) B) Evolution of the interatomic distances of contacts (I) – (V) over the MD timescale. In each plot, the adopted cutoff (5.5 Å) is shown as a dashed black line.




Figure S11. A) RMSD plot of the backbone atoms of *i*RGD in complex with $\alpha v\beta 3$ computed respect to the PT-WTE-predicted conformation of the peptide (B). Stability of the two intramolecular H-bonds (C and D) found in PT-WTE between Arg²(C-O)-Gly⁶(N-H) and Arg²(N-H)-Pro⁷(C-O), respectively.




Figure S12. A) RMSD plot of the backbone atoms of *i*RGD in complex α v β 5 computed respect to the PT-WTE-predicted conformation of the peptide (B). Stability of the two intramolecular H-bonds (C and D) found in PT-WTE between Arg² (C-O)-Gly⁶ (N-H) and Arg² (N-H)-Pro⁷ (C-O), respectively.




Figure S13. Analysis of the *i*RGD- α v β 6 residues interactions along the MD simulation. A) Frequency of Occurrence (% of collected frames in which the contact is formed) of the interatomic interactions: (I) Arg² (C ζ atom) – (α v)-D218 (C γ atom); (II) Asp⁴ (C ζ atom) – (β 6)-Mg²⁺; Arg² (C ζ atom) – (α v)-D150 (C γ atom); (IV) Gly³ (backbone-O atom) – (β 6)-Mg²⁺; (V) Lys⁵ (N ζ) – (β 6)-E174 (C ϵ -atom); (VI) Lys⁵ (N ζ) – (β 6)-S181 (O γ atom) B) Evolution of the interatomic distances of contacts (I) – (VI) over the MD timescale. In each plot, the adopted cutoff (5.5 Å) is shown as a dashed black line.




Figure S14. 3D representation of the unusual Mg^{2+} -chelation scheme and binding pattern experienced by *i*RGD in the $\alpha v\beta 6$ receptor. The receptor is depicted as light gray (αv subunit) and green ($\beta 6$ subunit) surfaces. The ligand backbone is shown in orange (initial MD frame) cartoons, while the sidechain of Arg^2 and Asp^4 are as shown as sticks to highlight the loss of typical RGD binding pattern: the interaction of Arg^2 with (αv)-D218 is lost and replaced by a salt-bridge with (αv)-D150, while the Mg^{2+} cation (purple sphere) is chelated by both the Asp^4 carboxylate and the backbone carbonyl of Gly^2 , leading to a distortion in the backbone conformation of the peptide.




Figure S15. Comparison of the dihedral values assumed by *i*RGD's ϕ - Gly^3 and ψ - Asp^4 in the three MD trajectories (A, B, C) with all the available experimental structures of RGD peptides in complex with RGD-integrin receptors. In each plot, the torsion values observed during the simulations are shown as dots colored based on their timestep. The ϕ - Gly^3 and ψ - Asp^4 values measured in the experimental structures are depicted as black triangle markers. The list of the PDBs used for the analysis is the following: 2VDM, 2VDN, 2VDO, 2VDP, 2VDQ, 2VDR, 3ZDY, 3ZDZ, 3ZE0, 3ZE1, 3ZE2, 4WK4, 4WK2, 4WK0, 3VI4, 4MMZ, 4MMY, 4MMX, 1L5G, 6MK0, 6MSL, 4UM9, 5FFO.




Figure S16. A) RMSD plot of the backbone atoms of *i*RGD in complex with $\alpha 5\beta 6$ computed respect to the PT-WTE-predicted conformation of the peptide (B). Stability of the two intramolecular H-bonds (C and D) found in PT-WTE between Arg²(C-O)-Gly⁶(N-H) and Arg²(N-H)-Pro⁷(C-O), respectively.




Figure S17. Schematic representation of the secondary structure elements of the integrins RGD binding site and SDL cavity. αV subunit is shown as gray cartoon while a generic β^* subunit is shown in beige.




Figure S18. 3D representation of the RGD binding site of $\alpha\text{v}\beta\text{3}$ (A), $\alpha\text{v}\beta\text{5}$ (B) and $\alpha\text{v}\beta\text{6}$ (C) receptors. The most important mutations occurring at the SDL subpocket were highlighted in sticks. The different receptors subunits are depicted as colored surfaces (αv =grey, β3 =red, β5 =cyan and β6 =green).




Figure S19. Superposition of the crystal structure of cilengitide at $\alpha\beta3$ (PDB code: 1L5G) with the MD-predicted binding pose of *i*RGD at $\alpha\beta3$ (A) and $\alpha\beta5$ (B). *i*RGD is shown as orange sticks and ribbon, while cilengitide is colored in white. The different receptors subunits are depicted as colored surfaces (αV =grey, $\beta3$ =red, $\beta5$ =cyan).




Figure S20. Results of the PT-WTE calculations on the designed compounds 3-7. All the shown FES were computed after 150 ns (per replica) of simulation. As for the parent peptide 1, in all the cases metadynamics converged after about 80-100 ns. Convergence was estimated as described in the Materials and Methods section for compound 1. The average exchange acceptance ratio was $\approx 25\%$.




Figure S21. Results of the PT-WTE calculations on the designed compounds **8-11**. All the shown FES were computed after 150 ns (per replica) of simulation. As for the parent peptide **1**, in all the cases metadynamics converged after about 80-100 ns. Convergence was estimated as described in the Materials and Methods section for compound **1**. The average exchange acceptance ratio was $\approx 25\%$.